Optimi Health Corp. announced a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components. The extraction process uses a highly viscous material to isolate key components of psychedelic mushrooms and dissolves the psilocybin into a molecular solution.

Using the same energy, the active ingredients are then repelled into the skin when applied topically. Due to the skin's highly permeable membrane, Optimi's solution has a natural time-release effect, which allows for a more sustained release into the body and provides a patient with the ability to experience the desired outcome for longer periods of time. Containing all GRAS certified ingredients, this solution can then be loaded into proprietary drug delivery system for direct passage through the skin into the bloodstream.

Transdermal application avoids the first pass metabolism and degradation of psilocybin by the liver that occurs with traditional oral drug delivery, which increases bioavailability of the active ingredient. In the continued effort to champion all things natural, Optimi's delivery system has been designed to require no additional shuttling agents. Instead, the repulsion technology steadily pushes the active ingredient through the various layers of the skin, and treatment begins almost immediately upon application.

This new process will help to reduce costs and resources while providing patients with a superior product. Optimi is focused on providing patients with a safe, consistent, and pure psychedelic product. Developing multiple extraction and delivery system methods is part of the Company's commitment to ensuring patients have options when deciding their treatment.